GSK has recruited China-based Clover Biopharmaceuticals, to help develop its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer). Under the new agreement, GSK says it will provide Clover with its pandemic adjuvant system for further evaluation of S-Trimer in preclinical studies, in hopes that Clover could potentially rapidly scale-up and produce large-quantities of a new coronavirus vaccine.
It was recently revealed that the UK would administer all babies with the hepatitis B vaccine to reduce the risk for young children, who are most risk should they catch the virus. Now, it has been revealed that manufacturing issues could cause severe shortages to administer the vaccine to those in need. Public Health England
GlaxoSmithKline’s meningitis B vaccine, Bexsero, has shown to have a dramatic impact on meningitis B cases within the UK, according to a real-world evidence study. Approximately a year ago the world’s first national meningitis B vaccination campaign was launched, after 10 months there have been reported cases of meningitis B drop 50% compared to the
The EU’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of potentially the first corrective ex vivo gene therapy for children anywhere in the world. GlaxoSmithKline received the green light from the CHMP for Strimvelis as a treatment for the rare disease ADA-SCID. Which is combined immunodeficiency due to adenosine deaminase
GlaxoSmithKline (GSK) and the UK’s Medical Research Council (MRC) will be collaborating in an open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will bring together researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL, with GSK scientists
GSK Invests £25 Million into their Montrose, Scotland FacilityGlaxoSmithKline (GSK) have announced that they will invest £25 million to bring production of ingredients for four new pharmaceutical products to their site in Montrose, Scotland. The investment is expected to create 25 new jobs for process technicians, engineers and chemists, increasing the total GlaxoSmithKline workforce in
Pharmaceutical drug maker, GlaxoSmithKline (GSK), today announced that their revenue increased just 1% in the first quarter, reflecting burdens on the organisation from government price cuts in Europe and some emerging markets, and hard year-by-year comparisons. GSK’s results were boosted by the sale of U.S. rights to a bladder drug, which added approximately £170 million
In confirming its unsolicited $2.60 billion offer for Human Genome Sciences (HGS), which was rejected, GlaxoSmithKline (GSK) commented that they still hope to push through the bid “on a friendly basis.” The UK drugs manufacturer noted that the $13.00 per share offer represented an 81% premium to Human Genome Sciences’ stock price on April 18,
